Wille Finance AG

You may also be interested in

BioXpress Therapeutics SA

BioXpress Therapeutics SA is exclusively focused on the development of biosimilars. With a philosophy that everyone should have access to high quality biologic therapeutics, BioXpress brings speed, efficiency and safety in developing biosimilar mAbs that impact patients’ quality of life.
1202 Geneva

Not a member

Adoram Therapeutics SA

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).
1212 Grand-Lancy

Member

Hengrui Europe Biosciences AG

Hengrui Europe Biosciences is a biotech start-up based in Zurich, Switzerland, established in 2021. We are a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. and are building a new research center with a differentiated technology platform to support innovative antibody discovery research.
8048 Zürich